Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer

This study has been completed.

Study NCT00079118 Information provided by National Cancer Institute (NCI)

First Received: March 8, 2004 Last Updated: December 23, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Publications:

Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2009 Jul 22; [Epub ahead of print]

Tan WW, Hillman D, Salim M, et al.: N0332 phase II trial of weekly irinotecan and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group trial. [Abstract] Breast Cancer Res Treat 106 (1): A-1087, S71-2, 2007.